T cell replacement therapy - Kiadis Pharma

Drug Profile

T cell replacement therapy - Kiadis Pharma

Alternative Names: ATIR; ATIR-101; ATIR-201; ATIR101; Reviroc™; Rhitol™; T cell replacement therapy TH9402; TH-9402

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Montreal
  • Developer Kiadis Pharma
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Bone marrow transplant rejection; Transplant rejection; Follicular lymphoma; Graft-versus-host disease; B cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Graft-versus-host disease
  • Phase III Acute myeloid leukaemia
  • Phase II Bone marrow transplant rejection; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Beta-thalassaemia
  • Discontinued Chronic myeloid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Aug 2018 Kiadis Pharma expects conditional approval from European Commission for Graft-versus-host disease (Adjunctive treatment, Prevention) in first quarter 2019
  • 01 Aug 2018 Kiadis Pharma expects to receive a Committee for Medicinal Products for Human Use opinion for Graft-versus-host disease (Adjunctive treatment, Prevention) in Q4 2018
  • 12 Mar 2018 Kiadis Pharma plans a clinical trial for Graft-versus-host disease in conjunction with another T-cell depleted haematopoietic stem cell transplantation (HSCT) protocol or with a cyclophosphamide-based haplo transplantation protocol
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top